Your browser doesn't support javascript.
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Chris Davis; Nicola Logan; Grace Tyson; Richard Orton; William Harvey; John Haughney; Jon Perkins; - The COVID-19 Genomics UK (COG-UK) Consortium; Thomas Peacock; Wendy S Barclay; Peter Cherepanov; Massimo Palmarini; Pablo R Murcia; Arvind H Patel; David L Robertson; Emma C Thomson; Brian James Willett.
  • Chris Davis; University of Glasgow
  • Nicola Logan; University of Glasgow
  • Grace Tyson; University of Glasgow
  • Richard Orton; University of Glasgow
  • William Harvey; University of Glasgow
  • John Haughney; Queen Elizabeth University Hospital
  • Jon Perkins; Queen Elizabeth University Hospital
  • - The COVID-19 Genomics UK (COG-UK) Consortium;
  • Thomas Peacock; Imperial College London
  • Wendy S Barclay; Imperial College London
  • Peter Cherepanov; The Francis Crick Institute
  • Massimo Palmarini; University of Glasgow
  • Pablo R Murcia; University of Glasgow
  • Arvind H Patel; University of Glasgow
  • David L Robertson; University of Glasgow
  • Emma C Thomson; University of Glasgow
  • Brian James Willett; University of Glasgow
Preprint in English | medRxiv | ID: ppmedrxiv-21259327
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
Vaccines are proving to be highly effective in controlling hospitalisation and deaths associated with SARS-CoV-2 infection but the emergence of viral variants with novel antigenic profiles threatens to diminish their efficacy. Assessment of the ability of sera from vaccine recipients to neutralise SARS-CoV-2 variants will inform the success of strategies for minimising COVID19 cases and the design of effective antigenic formulations. Here, we examine the sensitivity of variants of concern (VOCs) representative of the B.1.617.1 and B.1.617.2 (first associated with infections in India) and B.1.351 (first associated with infection in South Africa) lineages of SARS-CoV-2 to neutralisation by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines. Across all vaccinated individuals, the spike glycoproteins from B.1.617.1 and B.1.617.2 conferred reductions in neutralisation of 4.31 and 5.11-fold respectively. The reduction seen with the B.1.617.2 lineage approached that conferred by the glycoprotein from B.1.351 (South African) variant (6.29-fold reduction) that is known to be associated with reduced vaccine efficacy. Neutralising antibody titres elicited by vaccination with two doses of BNT162b2 were significantly higher than those elicited by vaccination with two doses of ChAdOx1. Fold decreases in the magnitude of neutralisation titre following two doses of BNT162b2, conferred reductions in titre of 7.77, 11.30 and 9.56-fold respectively to B.1.617.1, B.1.617.2 and B.1.351 pseudoviruses, the reduction in neutralisation of the delta variant B.1.617.2 surpassing that of B.1.351. Fold changes in those vaccinated with two doses of ChAdOx1 were 0.69, 4.01 and 1.48 respectively. The accumulation of mutations in these VOCs, and others, demonstrate the quantifiable risk of antigenic drift and subsequent reduction in vaccine efficacy. Accordingly, booster vaccines based on updated variants are likely to be required over time to prevent productive infection. This study also suggests that two dose regimes of vaccine are required for maximal BNT162b2 and ChAdOx1-induced immunity.
Full text: Available Collection: Preprints Database: medRxiv Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint





Full text: Available Collection: Preprints Database: medRxiv Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint